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The problem of infections due to antibiotic-
resistant staphylococci is one of increasing con-
cern to the medical profession. A large body of
data on this subject has been accumulated and
reported (1, 4, 6, 15) by clinicians and laboratory
workers in all parts of the world. The vast
majority of these studies refer to experience in
hospitalized patients and the role of systemic
antibiotic therapy as an important contributory
factor to the increased incidence of such infec-
tions has been emphasized.
In this paper we are reporting our observations
regarding the emergence of antibiotic-resistant
Staphylococcus aureus following the topical
treatment of cutaneous bacterial infections with
various types of antibiotic ointments. Almost
all of these patients who had local antibiotic
therapy were observed in the outpatient depart-
ment. As far as we know, except for sporadic
cases which have been recorded (1), definite
information (with bacterial cultures and antibio-
grams before and after local antibiotic treatment)
regarding this facet of the antibiotic-resistant
staphylococcus problem, is not available in the
literature. In addition, we have included similar
data for a smaller group of patients with cuta-
neous bacterial infections who were treated with
antibiotics administered systemically.
It is not within the scope of this paper to review
the literature on staphylococcal infections, but it
does seem pertinent to summarize briefly those
features of the problem with which all practicing
physicians should be familiar.
Staphylococci are becoming the most impor-
tant and most common cause of bacterial infec-
tions (2).
Staphylococcal infections resulting from cross-
infections within hospitals may be the most
serious current communicable disease problem
(3).
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The percentage of strains of staphylococci
resistant to antibiotics is related directly to the
extent which the particular antibiotics are used
(4, 5). However, there is very little evidence of
increasing resistance to neomycin and bacitracin
(5).
The percentage of antibiotic resistant strains
of staphylococci is greater in hospitalized patients
than in out-patients and the incidence of such
strains is still lower in the general population
(6, 7). The strains of staphylococci, isolated from
physicians, nurses, and other hospital personnel
in a given hospital, are often of the same phage
types as those from the patients in that hospital,
and a similar proportion of strains are antibiotic-
resistant (6).
Severe, sometimes fatal, staphylococcal enter-
itis developing after prophylactic and therapeutic
use of the broad spectrum antibiotics, has been
reported (8).
There is evidence of an existing tendency for
the increased occurrence of infections due to
antibiotic-resistant strains of staphylococci in
patients treated at home (6).
Antibiotic-resistant staphylococcal infections
may occur among two or more members of
families, and in some of these cases, infections
may be traced by phage typing studies to one
member of the family (especially infants) who
acquired it in the hospital. In other instances,
family infections may be independent of any
hospital association (9).
Bacterial cultures and in vitro susceptibility
tests are essential for the selection of the anti-
biotics to be used in the management of staphylo-
coccal infections (5).
METHODS
Selection of Cases. A total of 354 patients were
included in this study. They were selected on the
basis of the following criteria: (1) Presence of an
apparent clinical primary cutaneous infection,
such as impetigo, furunculosis, etc., or a probable
bacterial infection factor complicating contact
dermatitis, atopic dermatitis or eczematous der-
matitis of unknown etiology; (2) Isolation from
involved sites, before therapy, of Staph. aureus
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susceptible to the antimotic wnsen was adminis-
tered systemically or applied topically; (3) Avail-
ability of follow-up cultures after varying periods
of time following the antibiotic therapy.
Methods of Administration and Dosage. Topical
antibiotic therapy either with tetracycline oint-
ment, erythromyein ointment, neomycin oint-
ment, baeitraein ointment, or combination
neomycin-baeitraein ointment, was used in 245
eases. The only therapy for another 17 patients
was the ointment base which was used in the prep-
aration of the antibiotic ointments (control group).
Systemic antibiotic therapy, either with tetra-
cycline, erythromycin or novobiocin was used in
92 patients.
In almost all patients the dosage of tetracycline
and erythromyein was 250 mgs. every six hours;
in a few patients 500 mgs. every six hours was
prescribed for the first 48 to 72 hours of therapy.
The concentrations of the antibiotic ointments
were as follows: 1% erythromyein, 1% tetracyc-
line, 0.5% neomycin, 500 units baeitraein/gm,
and a combination of 0.5% neomyein and 500 units
baeitraein/gm. Usually the ointment base for the
topical preparations was eholesterinized petro-
latum, although in some patients the vehicle was
a vanishing type base. A small percentage of the
patients included in the tetracycline ointment
group used a combination hydroeortisone-tetra-
cyeline preparation.
Laboratory Methods. Specimens for cultures
were taken by using sterile saline-soaked cotton
swabs. These were streaked on blood agar plates
and incubated at 37°C for at least 48 hours. Cul-
tures showing no growth at that time were dis-
carded. Organisms were isolated and identified by
conventional bacteriological methods. The classi-
fication used is that of Bergey's Manual of Determi-
native Bacteriology, Seventh Edition. Antibiotic
susceptibility was tested by the disc method using
Sensi-Discs (BBL). In addition, several hundred
tests were done by the tube dilution technic.
Investigative work (10) which has been done in
our Department of Dermatology Research Labo-
ratory, as well as the numerous reports of others
(11, 12) show the two technics to be well corre-
lated. In this study, we were interested primarily
in the antibiotic susceptibility patterns (antibio-
grams) of Staph. eureus isolated before and after
antibiotic treatment. We have divided these anti-
biograms into 9 groups (See Table III).
Bacterial susceptibility tests with tetracycline,
neomyein, erythromyein, penicillin and novobio-
em were done in all eases. Chloramphenieol,
bacitraein, and streptomycin susceptibility tests
were done in many cases but not for all of the
organisms included in this study. Tests with strep-
tomyein were done whenever the organism was
resistant to tetracycline, erythromycin and peni-
cillin; therefore, streptomycin was a part of the
antibiogram only in groups VIII and IX (Table
III). At present, ehloramphenicol and streptomy-
cia are included in our routine susceptibility
tests for staphylococci, and the numerical designa-
tion of antibiograms proposed by one of us (13) is
used.
RESULTS
In Tables 1, II, III and IV, the results of the
therapeutic trials, correlated with the cultures
and antibiograms of Ste ph. aureus which were
isolated before and after systemic and local anti-
biotic therapy, are summarized. There was a
change from a susceptible to a resistant antibio-
gram in 17 of the 92 patients treated with sys-
temic antibiotic therapy and in 16 of the 136
patients treated with either tetracycline ointment
or erythromycin ointment. Of the 109 patients
treated topically with neomycin, baeitraein, or
the combination of neomyein-baeitraein, there
was either no change in the antibiogram or Staph.
aureus was not isolated following treatment. In
addition there was no change in the antibiogram
of Staph. aureus isolated before and after the use
of the control ointment base in 17 patients.
Of the 11 patients from whom antibiotic-resist-
ant staphylococci were cultured following sys-
temic therapy with tetracycline, 8 were
in-patients on the Dermatology Service and 3
were treated as out-patients; it is interesting that
emergence of antibiotic-resistant organisms was
observed in S of the 9 in-patients who were treated
with tetracycline. Only 2 of 11 in-patients treated
with erythromycin orally had this same sequence
of events (Table IV).
Almost all of the patients who were treated
with antibiotic ointments were out-patients.
Our experience does not justify any conclusion
regarding the relative incidence of emergence of
antibiotic-resistant Staph. aureus following topi-
cal therapy for skin infections in patients who are
treated in the hospital as compared with out-
patients.
No difference in age or sex groups was found,
nor did the type of cutaneous bacterial infection
treated influence the tendency for development
of antibiotic-resistant strains. The site of involve-
ment did not appear to be a factor.
The change in antibiograms occurred within a
period of seven days or less in 15 of the 33 pa-
S. H.
H. B.
C. B.
F. A.
P. L.
Ecz. derm., imp.t
Furuncle
Ecs. derm., imp.
Contact dermatitis,
impetiginized
Ecz. derm., imp.
Ecz. dcrm., imp., with
cellulitis
Ecz. derm., imp.
Ecz. derm., imp.
Ulcer, chronic
Ecz. derm., imp., with
lymphangitis
Ecz. derm., imp.
Ecz. derm., "nummu-
lar" type
Ecz. derm., imp.
Furunculosis
Furuncle
Ecz. derm., imp.
Furuncle
Impetigo and
Paronychia
Ecz. derm., imp.
Ecz. derm., imp.
Ecz. derm., imp.
Dyshidrotic eruption
Atopic dermatitis,
impetiginized
Atopic dermatitis,
impetiginized
Ecz. derm., imp.
Ecz. derm., imp.
Ecz. dcrm., imp.
Ecz. derm., ankles
Otitis externa
Tinea pedis,
impetiginized
Ecz. derm., imp.
Ecz. derm., imp.
Ulcers, leg, probably
factitial
Tetracycline
Tetracycline
Tetracycline
Tetracycline
Tetracycline
Tetracycline
Tetracycline
Tetracycline
Tetracycline
Tetracycline
Tetracycline
Erythromycin
Erythromycin
Erythromycin
Erythromycin
Erythromycin
Novobiocin
Tetracycline ointment
Tetracycline-
Hydrocortisone
ointment
Tetracycline ointment
Tetracycline ointment
Tetracycline ointment
Tetracycline-Hydro-
cortisone ointment
Tetracycline-Hydro-
cortisone ointment
Tetracycline ointment
Tetracycline ointment
Tetracycline ointment
Tetracycline ointment
Tetracycline cream
Terramycin-Poly-
myxin-B ointment
Erythromycin
ointment
Erythromycin
ointment
Erythromycin ointment
IP—7 days
IP—5 days
OP—16 days
IP—16 days
TP—13 days
IP—4 days
OP—19 days
IP—8 days
OP—4 days
OP—9 days
OP—l4 days
OP—17 days
OP—S days
OP—14 days
TABLE I
Tabulation of cases
Antibiotic Resistant Staph. Aureus Cultured at Site of Cutaneous Infection after Systemic or Local
Antibiotic Treatment
Diagnosis Antibiotic Doration ofTreatment* Site of Involvement
Ifl—4 days
IP—1 1 days
OP*—5 days
IP—7 days
L. S.
J. K.
M. K.
E. S.
J. L.
R. S.
H. A.
W. H.
S. B.
A. C.
W. N
J. N.
M. G.
P. B.
J. K.
A. K.
L. C.
T. C.
J. C.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
OP—2 days
OP—28 days
IP—3 days
OP—18 days
IP—23 days
OP—6 days
IP—7 days
OP—16 days
OP—is days
OP—7 days
OP—23 days
OP—9 days
OP—i4 days
Extremities
Neck and arm
Hands
Hands
Arms, legs, hand
Feet
Arms and legs
Hands and feet
Leg
Hands
Hands
Extremities
Feet
Multiple sites
Neck and arm
Hands
Upper lip
Feet
Foot
Hands
Hands and feet
Hands
Hands
Face, extremities
Hands
Ankle
Feet
Legs
External audi-
tory canal
Feet
Hands and feet
Hands
Leg
A. K.
H. H.
E. W.
M. F.
M. S.
C. J.
C. L.
B. T.
W. N.
OP—27 days
OP—7 days
IP—4 days
* Duration of treatment refers to the number of days between culture done at time of initiation of
therapy and the first culture showing emergence of antibiotic resistant Staph. aureus.
t Abbreviation for Eczematous dermatitis, impetiginized.
In-patient.
§ Out-patient.
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TABLE II
Summary of results regarding emergence of resistant
Staph. aureus following oral and topical antibiotic
therapy
Total No.
Cases Resistant
Tetracycline (oral) 40 11
Erythromycin (oral) 49 5
Novobiocin (oral) 3 1
Tetracycline ointment 117* 13t
Erythromycin ointment 19 3
Neomycin-Bacitracin ointment. 69 0
Neomycin ointment or lotion. . 26 0
Bacitracin ointment 14 0
Control ointment base 17 0
Total 354 33
* Includes 2 patients on Oxytetracycline oint-
ment.
I Includes 1 patient on Oxytetracycline oint-
ment.
tients; there might have been more patients in
this group if cultures had been done more fre-
quently.
In 10 of these 33 patients, therapeutic response
was quite satisfactory in that essentially the
bacterial infection component of the dermatitis
had disappeared or was minimal at the time that
the antibiotic-resistant staphylococcus was iso-
lated. In this regard, it seems significant that in
7 of these 10 patients with a favorable response,
both Streptococcus pyo genes and Staph. aureus
were isolated prior to treatment.
In 17 patients of this group, the infection did
not appear to improve significantly following
antibiotic therapy; Strep. pyogenes and Staph.
aureus were cultured before treatment in only 3
of these 17 patients.
In 6 of the 33 patients, the emergence of the
antibiotic-resistant staphylococci was accom-
panied by an adverse effect on the course of the
infection. In these cases, the patient's infection
either improved initially, and then there was a
significant relapse, or new suppurative lesions
developed during the course of treatment. This
sequence of events was illustrated dramatically
in Case No. 23, in that the use of tetracycline
ointment was followed by very rapid improve-
ment of a severe impetiginized eczematous
dermatitis of the hands. The relatively severe
bacterial infection complicating this patient's
dermatitis cleared completely within a period of
8 days, but this was followed by a very definite
relapse of the infection at the same time that
Staph. aureus, resistant to tetracycline, was
cultured. Following this, there was another period
of marked improvement of the infection when
other antibiotic therapy was prescribed.
The results of bacterial cultures subsequent to
the completion of antibiotic therapy were avail-
able for 17 of the 33 patients. In 8 cases, Staph.
aureus with the same resistant antibiogram was
cultured after periods of time varying from one
month to 9 months. In 6 other patients, Staph.
aureus, which was cultured weeks or months later,
was not resistant (antibiogram Group I or II).
In 3 patients, Staph. aureus was not cultured
during periods of time varying from 10 days to
one month, despite the previous isolation of
antibiotic resistant staphylococci at the end of
therapy. No such data are available for the other
16 patients.
In Table III, the antibiograms of the staphylo-
cocci which were isolated from the antibiotic
resistant cases before and after treatment are
tabulated. Before therapy, 26 of the 33 strains of
Staph. aureus were either susceptible to all anti-
biotics tested or resistant only to penicillin (8
cases). After treatment periods varying from 2
days to 28 days, 30 of 33 strains were resistant to
penicillin, and 27 were resistant to one or more
broad spectrum antibiotics as well as to penicillin;
9 strains were resistant to erythromycin, tetra-
cycline and penicillin.
COMMENT
As Barber and Burston (1) have emphasized,
the mode or origin of antibiotic staphylococci is
a complex subject. For example, some strains of
staphylococci produce penicillinase which mac-
tivates penicillin. Such a mechanism has not
been recognized for other antibiotics. One ex-
planation for the emergence of resistant bacteria
is that there exists in a population of antibiotic-
susceptible staphylococci a few organisms which
are naturally resistant and during antibiotic
therapy there is destruction or inhibition of the
susceptible bacteria with survival of a few
resistant ones. This permits a replacement of the
susceptible by the resistant organisms resulting
in the emergence of an antibiotic-resistant strain
of staphylococci.
The emergence of antibiotic-resistant staphylo-
cocci in 17 of our 89 patients with cutaneous
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TABLE III
Antibiograms of Staph. aureus
Isolated Before and After Treatment
Case No. Antibiogram Before II Antibiogram After P Case No. Antibiogram Before 11 Antibiogram After II
1 Group VII Group VIII 18 Group II Group VI
2 Group II Group VI 19 Group II Group VI
3 Group IV Group VI 20 Group I Group VI
4 Group I Group VI 21 Group I Group III
5 Group I Group VT 22 Group I Group VI
6 Group I Group VI 23 Group I Group VIII
7 Group I Group VI 24 Group I Group VI
8 Group I Group III 25 Group I Group VI
9 Group II Group VI 26 Group I Group VI
10 Group II Group VI 27 Group I Group VI
11 Group II Group VI 28 Group I Group VIII
12 Group II Group IX 29 Group I Group III
13 Group I Group VIII 30 Group I Group VT
14 Group VI Group VIII 31 Group VI Group VIII
15 Group VT Group VIII 32 Group II Group IV
16 Group VI Group VIII 33 Group I Group VIII
17 Group VI Group V
All strains were susceptible to neomycin and all except two were susceptible to novobiocin.
Group I Susceptible to T, E and P
Group II Susceptible to T and E; resistant to P
Group III Susceptible to E and P; resistant to T
Group IV Susceptible to T and P; resistant to E
Group V Susceptible to T, E and P; resistant to N
Group VI Susceptible to E; resistant to T and P
Group VII Susceptible to T; resistant to E and P
Group VIII Resistant to T, E, P and S
Group IX Resistant to T, E, P, S and N
(T, E, P, S and N are abbreviations for Tetracycline, Erythromyciri, Penicillin, Streptomycin and
Novobiocin.)
bacterial infections who were treated with either
tetracycline, erythromycin, or novobiocin system-
ically is not surprising. A possible explanation for
the difference in results following the administra-
tion of these antibiotics is that in our hospital,
erythromycin has been used less frequently than
tetracycline and a much higher percentage of
Staph. aureus is resistant to tetracycline than to
erythromycin. In studies, which primarily have
involved patients in hospitals, many investigators
have emphasized the direct correlation between
the increased use of antibiotics systemically and
an increase in incidence of antibiotic-resistant
strains of staphylococci.
We have not found similar data in the literature
regarding the effect of topical antibiotic therapy
in emergence of antibiotic-resistant strains of
staphylococci except for 4 patients with skin
infections recorded by Barber and Burston (1).
The primary diagnoses in these 4 patients were
pemphigus, contact dermatitis, extensive exfolia-
tive dermatitis and leg ulcer. The first three pa-
tients had been treated with chlortetracycline
ointment, the fourth with streptomycin and
chloramphenicol ointments. Cultures were not
done before therapy, but staphylococci, resistant
to penicillin, streptomycin, and the tetracylines
and to these antibiotics plus chloramphenicol in
the latter two cases, were isolated after the pro-
longed local antibiotic treatment noted above.
These authors advised against the prolonged use
of topical antibiotic preparations, except for
neomycin, which they consider probably the
most suitable agent for the local treatment of
staphylococcal lesions.
It is significant that in our series of 109 patients,
the emergence of antibiotic-resistant Staph.
aureus was not noted in a single case following
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TABLE IV
Number of patients treated in hospital and as out-
patients
In-
Patients
Out-
Patients
Total
Cases
Tetracycline (oral) 9 (8Y 31 (3) 40
Erythromycin (oral) 11 (2) 38 (3) 49
Novobiocin (oral) 2 (1) 1 (0) 3
Tetracycline ointment 4 (1) 113 (12) 117
Erythromycin ointment.. . 4 (1) 15 (2) 19
Neomycin-Bacitracin oint-
ment 2 (0) 67 (0) 69
Neomycin ointment or lo-
tion 4 (0) 22 (0) 26
Bacitracin ointment 0 14 (0) 14
Control ointment base. . . . 1 (0) 16 (0) 17
Total 37 317 354
* Number of patients in whom there was emer-
gence of antibiotic resistant Staph. aureus in pa-
renthesis.
treatment with neomycin ointment, bacitracin
ointment, or the combination neomycin-bacitra-
cm ointment. Neomycin is an effective therapeu-
tic agent for the topical treatment of cutaneous
staphylococcal infections. However, it has been
our experience that neomycin is not as effective
as tetracycline in the local treatment of cutaneous
bacterial infections if, on culture, Strep. pyogenes
is either the only isolate or a part of the flora.
Another factor which we consider important in
regard to the use of topical preparations con-
taining neomycin is that in recent years there has
been a tendency for a small increase in the number
of sensitization reactions to this antibiotic. It has
been our experience that this undesirable se-
quence of events is more apt to occur in persons
who have atopic dermatitis, or chronic eczema-
tous dermatitis of the hands, feet, external
auditory canal, and intertriginous areas. Pro-
longed topical application of neomycin, especially
in patients with chronic dermatitis of any type,
increases the probability of such sensitization
reactions. It is for this reason that we do not use
neomycin routinely in combination with hydro-
cortisone when topical steroid therapy is indi-
cated. We believe that in general, if bacterial
infection is a significant factor and if topical
neomycin therapy is effective for the patient in
question, a favorable therapeutic result will occur
within a period of 7 to 14 days. If there is only
questionable improvement, discontinuing the
neomycin is in order. (This comment also applies
in the use of other topical antibiotic prepara-
tions.)
Very few deaths due to staphylocoecal septi-
cemia complicating cutaneous bacterial infections
have been recorded in the literature. Of 7 deaths
due to systemic staphylocoeeal infections re-
ported by Martin and his co-workers (14), one
was due to a skin infection complicating derma-
titis herpetiformis. During a period of three and
one half months, Wysham and Kirby (3) accumu-
lated a series of 189 hospitalized patients with
staphylococcal infections; 100 of these infections
appeared during the period of hospitalization and
in 32 additional patients, the infection had its on-
set within 60 days after discharge from the hospi-
tal. They reported 24 deaths; one of these pa-
tients who succumbed was an apparently healthy
forty-year-old male who had furunculosis com-
plicated by "mierococcal" septicemia and in 2
other patients, staphyloeoccal infection of third
degree burns was considered to be a major
contributory factor.
CONCLU5SON5
Our present policy regarding the use of sys-
temic and topical antibiotic therapy in the treat-
ment of cutaneous bacterial infections may be
summarized as follows:
Antibiotic therapy, both systemic and topical
is prescribed in a discriminate manner. An effort
is made to treat the patient specifically; the deci-
sion regarding the advisability of using antibiotic
therapy in a given case, the selection of the anti-
biotic, and the route of administration (systemic
or topical) are dictated by the cultural findings
and the clinical situation.
The combination neomyein-bacitracin oint-
ment* is preferred for the topical treatment of
infections due to Staph. aureus. The addition of
bacitracin increases the therapeutic effectiveness
if Strep. pyogenes is isolated either in pure
culture or as part of the bacterial flora. We avoid
the prolonged use of topical preparations con-
taining neomycin for patients who have second-
arily infected atopie dermatitis, chronic eczema-
tous dermatitis, or otitis externa.
If there is no significant improvement following
the use of neomycin-bacitracin ointment for from
5 to 7 days, and if it appears that it is in order to
* Mycitracin ointment (Upjohn) was used for
the patients included in this study.
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continue topical antibiotic treatment, a trial of
tetracycline ointment is instituted. It has been
our experience that tetracycline ointment is more
effective for cutaneous infections due to Strep.
pyo genes than the neomycin-baeitracin combina-
tion ointment; therefore, under these circum-
stances, if topical therapy is indicated, usually
tetracycline ointment is prescribed initially.
Discrimination in the use of antibiotics is
essential, particularly in hospital practice. It
must be assumed that the administration of
antibiotics systemically to patients who are
hospitalized with cutaneous bacterial infections
will be followed by the colonization of the skin
with antibiotic-resistant Staph. aureus in a rela-
tively high percentage of eases. This is of obvious
epidemiologic significance, and, in some patients,
this sequence of events will influence the course
of the patient's infection in an adverse manner.
The use of strict isolation teehnics in caring for
the in-patient with cutaneous bacterial infections
will decrease the tendency for colonization of the
skin lesions with the "hospital" strain of Staph.
aureus.
Emergence of antibiotic-resistant Staph.
aureus in skin lesions following either systemic
or topical antibiotic therapy for cutaneous infec-
tions is less likely in out-patients than in in-
patients. There is a need for more data regarding
the epidemiologic significance of the emergence
of antibiotic resistant Staph. aureus in the skin
lesions of out-patients following the use of either
systemic or topical antibiotic therapy for the
treatment of cutaneous infections.
At the present time, except under unusual
circumstances, we do not use erythromycin
ointment or chloramphenicol ointment.
In treating both in-patients and out-patients
with either systemic or topical antibiotic therapy,
it is essential to repeat cultures and antibiograms
if the course of the apparent bacterial infection is
not satisfactory. Relapse or absence of progres-
sive improvement following initial improvement,
may be due to the emergence of antibiotic-
resistant Staph. aureus.
sUMMARY
Our experience regarding the emergence of
antibiotic-resistant Staph. avreus in skin lesions
of patients with cutaneous bacterial infections,
following therapeutic trials with tetracycline
ointment, erythromyein ointment, neomyein
ointment (or lotion), bacitracin ointment, or
neomycin-bacitracin ointment, or after oral
administration of tetracycline, erythromycin,
or novobiocin is reported.
A total of 354 patients met the following
criteria for inclusion in this study: 1) Presence of
an apparent clinical primary or secondary cuta-
neous bacterial infection. 2) Isolation from
involved sites, before therapy, of Staph. aureus
susceptible to the antibiotic which was adminis-
tered systemically or applied topically. 3) Avail-
ability of follow-up cultures after varying periods
of time following the antibiotic therapy.
There was a change from a sensitive to a resist-
ant antibiogram in 16 of 136 patients treated with
either tetracycline or erythromycin ointment.
Of the 109 patients treated topically with either
neomycin, bacitracin, or the combination of
neomycin-bacitracin, there was either no change
in the antibiogram or Sta ph. aureus was not iso-
lated following treatment.
Emergence of antibiotic-resistant Staph. aureus
was noted in 17 of 92 patients with skin infections,
treated systemically with tetracycline, erythro-
mycin or novobiocin.
The problem of emergence of antibiotic resist-
ant Staph. aureus following the usc of topical
and systemic antibiotic therapy for the treatment
of cutaneous bacterial infections is of greater
significance in in-patients than in out-patients.
Our present policy regarding the use of sys-
temic and topical antibiotic therapy for the treat-
ment of bacterial infections of the skin is sum-
marized.
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DISCUSSION
DR. J. WALTER WiLsoN (Los Angeles, Calif):
Were the strains of staphylococci which were
called resistant by the authors the bacteriophage
types 52/S 1 or 42B—the notorious so-called
hospital strains?
I also want some clarification as to just how a
resistant strain emerges. This word emerge is
very good—all it means is that you don't see it
at first and sometime thereafter you do see it. I
wonder whether or not, actually, the material
which is put on the original sensitivity test can-
not contain tiny quantities of resistant organisms
as well as nonresistant ones to begin with, and
perhaps the latter are killed by the drug, leaving
the resistant ones. It is a little hard for me to
believe that new mutations can always produce
this 52/Si or some such species. I prefer to believe
that these strains are now scattered all over the
world and are simply being recovered in more
and more of our specimens.
DR. PETER BEAL (Redwood City, Calif.): I
would just like to ask if any attempt has been
made to follow up the recovered cases with cul-
tures of the nose and throat?
Many of our skin contaminants are bacteria in
most instances—often from the nose and throat.
I think it would be significant to know that once
you have discovered an antibiotic-resistant
organism on their skin—whether these individ-
uals actually harbor them in their nose and throat
and whether they might not be carriers that
might contaminate others.
DR. NORMAN N. EPSTEIN (San Francisco,
Calif.): Concerning the use of small doses of
antibiotics internally over a lung period of time,
such as in the treatment of acne vulgaris, I would
like to ask if Dr. Livinguod believes there is any
serious danger of the patient developing serious
evidence of antibiotic resistant disease?
DR. THEODORE COENIDLEET (Chicago, Illinois):
In those patients with resistant organisms who
went on to recovery, was the therapy changed?
If it was not, do you feel that the in vitro results
are relevant to the clinical findings?
DR. STEPHEN ROTRMAN (Chicago, Ill.): I was
very much impressed with what Dr. Livingood
has shown us. It seems that infections of the skin
may be cleared by antibiotics to which the organ-
isms are resistant in vitro.
In my experience, too, in vitro testing of sensi-
tivities has only limited clinical value. Non-
consistent therapeutic results are rather common.
DR. CLARENCE S. LIvIN000D (in closing): I
wish to thank the discussurs for their comments
and questions.
Dr. Wilson, the strains of Staph. aureus which
were isolated in this series of patients were not
phage typed. Our data regarding the emergence
of antibiotic resistant Staph. aureus in the 33 pa-
tients following either topical or systemic anti-
biotic therapy refer only to a change in the anti-
biogram of the organism, which may or may not
mean that different phage types of Staph. aureus
were isolated before and after treatment.
Dr. Wilson's suggestion that there might have
been a "killing off" of the sensitive organisms
because of the possibility of carrying over a small
amount of the antibiotic to the culture tube, is a
valid one. However, I do not think that this
sequence of events occurred in our cases. Topical
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antibiotic therapy was discontinued for a period
of approximately 12 hours before the follow-up
cultures were done. In some of our patients in-
cluded in this group, cultures were done one to
several weeks after treatment was discontinued.
Our experience in regard to the emergence of
antibiotic resistant ,Staph. aureus in the skin
lesions of patients who were hospitalized with
cutaneous bacterial infections and treated with
systemic antibiotic therapy is not unique. How-
ever, as far as we know, this is the largest group of
patients in whom emergence of antibiotic-resist-
ant Staph. aurevs has been observed following
topical antibiotic therapy with either tetracycline
ointment or erythromycin ointment. This se-
quence of events appears to occur in a larger
percentage of cases than we had anticipated. We
plan to evaluate the epidemiologic significance of
this finding, and in these studies, phage typing
of the strains of Staph. aureus will be essential. At
the present time, it seems doubtful that the use of
tetracycline ointment is resulting in a significant
increase of antibiotic resistant strains of Staph.
aureu.s in the general population. It is significant
that the topical application of neomycin or
bacitracin was not followed by the emergence of
antibiotic resistant strains of Staph. aureus or at
least not in our group of patients.
Dr. Norman Epstein has asked about the treat-
ment of acne with broad spectrum antibiotics.
Our data do not make it possible to answer his
question but this is another problem which we
are planning to investigate.
Dr. Rothman has asked a question regarding
the clinical course of our patients in whom there
was emergence of antibiotic-resistant Staph.
aureus following antibiotic therapy. Also, he has
stated that often there does not seem to be good
correlation between the therapeutic results with
antibiotics and in vitro sensitivity tests. In some
of our patients, the emergence of an antibiotic
resistant organism did not seem to have any
effect on the clinical course of the infection, but
in other cases, this sequence of events was accom-
panied either by failure to improve beyond a
certain point or by relapse of the infection. This
is covered in the paper in detail. It seems to me
that the practical point to be considered, is that,
in patients, who have bacterial infections due to
Staph. aureus, it is essential to repeat the cultures
and the antibiograms if the course of the infection
is not proceeding in a favorable maimer. The
reason for this is that in some cases, failure to
improve may be explained by the emergence of
an antibiotic resistant strain of Staph. aureus and
a change in therapy is indicated. It is not a simple
matter to correlate the clinical course of a staphy-
lococcal skin infection and the results of cultures
and in vitro sensitivity tests. For one thing, the
isolation of Staph. aureus does not mean neces-
sarily that the presenting eruption is a bacterial
infection either primary or dermatitis compli-
cated by staphylococcal infection. Therefore,
failure to improve with specific antibiotic therapy
for a sensitive strain of Staph. aureus may not
indicate poor correlation with the results of the
sensitivity tests since factors other than the
apparent infection may account for the failure
to improve. Furthermore, the same reasoning
may be used in attempting to explain improve-
ment following antibiotic therapy for a skin
lesion from which an antibiotic resistant strain
is isolated because isolation of Staph. aureus may
indicate colonization of the involved sites with no
pathogenic effect.
